About biologicals
Products that are regulated as biologicals include:
- tissue-based products (skin, bone, ocular, cardiovascular, amnion)
- cell-based products (genetically modified, in vitro cell expansion or depletion)
- immunotherapy products containing human cells
- combination products (for example, cell therapy and medical device)
- products that comprise or contain live animal cells, tissues or organs (for example, pancreatic islet cells isolated from pigs)
- autologous human cells and tissue products (including stem cells)
- faecal microbiota transplant (FMT) products (a thing that comprises, contains or is derived from human stool).
For detailed information on how we define and regulate biologicals go to What is regulated as a biological.
More information
-
PageUnderstand how we regulate human tissue and cell-derived products and live animal cell, tissues or organs in Australia.
-
PageHow we include new biologicals in the Australian Register of Therapeutic Goods (ARTG).
-
Accessing unapproved biologicals that are not on the Australian Register of Therapeutic Goods (ARTG)
GuidanceGuidance for people who want to access biologicals that are not included on the Australian Register of Therapeutic Goods (ARTG). -
GuidanceGuidance to explain how the intended use of a biological product influences its classification and exemptions.
-
PageUnderstand the potential health risks and legal implications for placenta consumption.
Faecal microbiota transplant
-
GuidanceGuidance for sponsors of faecal microbiota transplant (FMT) products, which are regulated as biologicals.
-
PageUnderstand how we regulate faecal microbiota transplant (FMT) products.
Latest articles
-
New UDI requirements for medical devices commence 1 July 2026
News articlesFrom 1 July 2026, some medical devices supplied in Australia must meet Unique Device Identification (UDI) requirements. -
Buying health products safely online
BlogYou might see a good deal on an overseas website, however, these health products are not approved for supply in Australia and have not been assessed by the TGA for safety, quality or effectiveness. You are not only risking your health, but you may also be left out of pocket if your online purchase is stopped at the border. -
New resources on market actions and minor PRAC updates
News articlesWe have published a new FAQ and Guidance page on the use of legislative powers related to recalls and other market actions.
Latest consultations
-
ConsultationWe are seeking industry feedback on proposed amendments to strengthen the legal framework governing TMFs for blood and blood components, and PMFs for Type II plasma-derived products.
-
ConsultationWe are seeking feedback on whether 19 international scientific guidelines should be adopted.
-
ConsultationHave your say on potential reforms to Part 5 of the Therapeutic Goods Regulations 1990.